{"id":"W2906110772","doi":"10.1016/j.jval.2018.09.103","title":"PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Population; Internal medicine; Lung cancer; Hazard ratio; Regimen; Cancer; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00652626,0.001533705,0.003963465,0.0008360625,0.0002923336,0.001405029,0.001382146,0.001674051,0.004607499],"category_scores_gemma":[0.009377304,0.000630345,0.01016214,0.0009242284,0.0007568327,0.001388703,0.001080572,0.002500772,0.0003494782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001863227,"about_ca_system_score_gemma":0.001119677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007273905,"about_ca_topic_score_gemma":0.007308656,"domain_scores_codex":[0.9920231,0.005846392,0.0005180003,0.0007649681,0.0004283531,0.0004192503],"domain_scores_gemma":[0.9948731,0.00322753,0.000848759,0.0003659627,0.0002756074,0.0004089643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9006904,0.001114076,0.01834475,0.001747229,0.05919019,0.00007422977,0.00009431827,0.002266636,0.0006081448,0.0002731956,0.0004860194,0.01511085],"study_design_scores_gemma":[0.4344028,0.187328,0.1688848,0.0007705019,0.1866175,0.0003216827,0.0003550515,0.01310745,0.0028693,0.001836888,0.003318256,0.0001878633],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826345,0.01172359,0.0005795074,0.0002633691,0.0004396203,0.0003589083,0.001888317,0.0000295519,0.002082758],"genre_scores_gemma":[0.9973235,0.0008443356,0.0002907475,0.0001098945,0.00005540431,0.0001450244,0.0008107485,0.0000047772,0.000415595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007273905,"threshold_uncertainty_score":0.03451461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.146381492280194,"score_gpt":0.4403910053062912,"score_spread":0.2940095130260972,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}